Regenxbio (RGNX) Stock
Gene therapy developer using AAV platform for inherited conditions. Here's the price, business snapshot, and what's worth knowing about Regenxbio in August 2026.
Regenxbio Inc (RGNX) is a clinical‑stage biotechnology company focused on developing gene therapies using its proprietary NAV AAV platform. Investors should know it centres on designing and delivering adeno‑associated virus (AAV) vectors to address a range of inherited and acquired conditions, and it supports programmes through partnerships and licensing. With a market capitalisation of approximately $661.23M, Regenxbio can offer upside tied to positive clinical readouts or successful collaborations, but it remains subject to the typical biotech risks: long development timelines, high R&D spend, binary trial results and regulatory uncertainty. The share price can be volatile and funding or dilution remains possible. This overview is general educational information and not personalised investment advice; Regenxbio may be suitable only for investors who understand and accept the high-risk, high-uncertainty nature of clinical-stage biotech investments.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying REGENXBIO's stock with a target price of $31.77, indicating strong growth potential.
Financial Health
REGENXBIO is producing moderate revenue and cash flow, but its financial outlook remains mixed.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
NAV AAV Platform
A proprietary AAV platform underpins many programmes and collaborations — it may enable broad applications, though development is costly and outcomes uncertain.
Clinical Milestones
Trial readouts and regulatory steps tend to drive share movements; positive data can increase value, while setbacks are common and may be swift.
Partnerships Matter
Collaborations can provide funding and expertise and help de‑risk programmes, but commercial returns depend on successful development and approvals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
